Pathologic Complete Response Prediction to Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: Real-World Evidence from Integrative Inflammatory and Nutritional Scores

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Lin Y, Totsuka Y, Shan B, et al. Esophageal cancer in high-risk areas of China: research progress and challenges. Ann Epidemiol. 2017;27(3):215–221. doi:10.1016/j.annepidem.2016.11.004
   PubMed Web of Science ®Google Scholar
• van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–2084. doi:10.1056/NEJMoa1112088
   PubMed Web of Science ®Google Scholar
• Kojima T, Shah MA, Muro K, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138–4148. doi:10.1200/JCO.20.01888
   PubMed Web of Science ®Google Scholar
• Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506–1517. doi:10.1016/S1470-2045(19)30626-6
   PubMed Web of Science ®Google Scholar
• Wu Z, Zheng Q, Chen H, et al. Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma. J Thorac Dis. 2021;13(6):3518–3528. doi:10.21037/jtd-21-340
   PubMed Web of Science ®Google Scholar
• Shen D, Chen Q, Wu J, et al. The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma. J Gastrointest Oncol. 2021;12(1):1–10. doi:10.21037/jgo-20-599
   PubMed Web of Science ®Google Scholar
• Xing W, Zhao L, Zheng Y, et al. The sequence of chemotherapy and toripalimab might influence the efficacy of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell cancer-A Phase II study. Front Immunol. 2021;12:772450. doi:10.3389/fimmu.2021.772450
   PubMed Web of Science ®Google Scholar
• Xing W, Zhao L, Fu X, et al. A phase II, single-centre trial of neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma. J Thorac Dis. 2020;12(11):6861–6867. doi:10.21037/jtd-20-2198
   PubMed Web of Science ®Google Scholar
• Zheng Y, Liu XB, Sun HB, et al. A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909). Ann Transl Med. 2021;9(1):73. doi:10.21037/atm-20-5404
   PubMed Web of Science ®Google Scholar
• Lu SL, Hsu FM, Tsai CL, et al. Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: hypothesis generating for adjuvant treatment. Eur J Surg Oncol. 2019;45(8):1498–1504. doi:10.1016/j.ejso.2019.03.020
   PubMed Web of Science ®Google Scholar
• McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12(3):223–226. doi:10.1097/MCO.0b013e32832a7902
   PubMed Web of Science ®Google Scholar
• Feng JF, Zhao JM, Chen S, et al. Naples prognostic score: a novel prognostic score in predicting cancer-specific survival in patients with resected esophageal squamous cell carcinoma. Front Oncol. 2021;11:652537. doi:10.3389/fonc.2021.652537
   PubMed Web of Science ®Google Scholar
• Graziano V, Grassadonia A, Iezzi L, et al. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast. 2019;44:33–38. doi:10.1016/j.breast.2018.12.014
   PubMed Web of Science ®Google Scholar
• Zhao K, Wang C, Shi F, et al. Lymphocyte-monocyte ratio as a predictive marker for pathological complete response to neoadjuvant therapy in esophageal squamous cell carcinoma. Transl Cancer Res. 2020;9(6):3842–3853. doi:10.21037/tcr-19-2849
   PubMed Web of Science ®Google Scholar
• Wu Y, Chen J, Zhao L, et al. Prediction of pathologic response to neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma incorporating hematological biomarkers. Cancer Res Treat. 2021;53(1):172–183. doi:10.4143/crt.2020.594
   PubMed Web of Science ®Google Scholar
• Eraslan E, Adas YG, Yildiz F, et al. Systemic immune-inflammation index (SII) predicts pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. J Coll Physicians Surg Pak. 2021;30(4):399–404. doi:10.29271/jcpsp.2021.04.399
   PubMed Web of Science ®Google Scholar
• Wu Y, Li J. Change in maximal esophageal wall thickness provides prediction of survival and recurrence in patients with esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy and surgery. Cancer Manag Res. 2021;13:2433–2445. doi:10.2147/CMAR.S295646
   PubMed Web of Science ®Google Scholar
• Zhang X, Gari A, Li M, et al. Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti-PD-1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma. J Transl Med. 2022;20(1):61. doi:10.1186/s12967-022-03252-7
   PubMed Web of Science ®Google Scholar
• Sabra MJ, Alwatari YA, Wolfe LG, et al. Ivor Lewis vs McKeown esophagectomy: analysis of operative outcomes from the ACS NSQIP database. Gen Thorac Cardiovasc Surg. 2020;68(4):370–379. doi:10.1007/s11748-020-01290-w
   PubMed Web of Science ®Google Scholar
• Zhang T, Hou X, Li Y, et al. Effectiveness and safety of minimally invasive Ivor Lewis and McKeown oesophagectomy in Chinese patients with stage IA-IIIB oesophageal squamous cell cancer: a multicentre, non-interventional and observational study. Interact Cardiovasc Thorac Surg. 2020;30(6):812–819. doi:10.1093/icvts/ivaa038
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191–1203. doi:10.1056/NEJMoa2032125
   PubMed Web of Science ®Google Scholar
• Kang X, Qin J, Zhang R, et al. 2021 NCC/CATS/CSTCVS/STM expert consensus on perioperative immunotherapy for esophageal cancer. Ann Esophagus. 2021;4:33. doi:10.21037/aoe-21-64
   Google Scholar
• Li J, Qiu R, Hu Y, et al. Postoperative adjuvant therapy for patients with pN+ esophageal squamous cell carcinoma. Biomed Res Int. 2021;2021:8571438. doi:10.1155/2021/8571438
   PubMed Web of Science ®Google Scholar
• Li L, Zhao L, Lin B, et al. Adjuvant therapeutic modalities following three-field lymph node dissection for stage II/III esophageal squamous cell carcinoma. J Cancer. 2017;8(11):2051–2059. doi:10.7150/jca.18981
   PubMed Web of Science ®Google Scholar
• Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103(7):1347–1355. doi:10.1002/cncr.20916
   PubMed Web of Science ®Google Scholar
• Rice TW, Ishwaran H, Hofstetter WL, et al. Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016;29(8):897–905. doi:10.1111/dote.12533
   PubMed Web of Science ®Google Scholar
• Feng JF, Wang L, Yang X. The preoperative hemoglobin, albumin, lymphocyte and platelet (HALP) score is a useful predictor in patients with resectable esophageal squamous cell carcinoma. Bosn J Basic Med Sci. 2021;21(6):773–781. doi:10.17305/bjbms.2021.5666
   PubMed Web of Science ®Google Scholar
• Budczies J, Klauschen F, Sinn BV, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One. 2012;7(12):e51862. doi:10.1371/journal.pone.0051862
   PubMed Web of Science ®Google Scholar
• Li TJ, Jiang YM, Hu YF, et al. Interleukin-17-producing neutrophils link inflammatory stimuli to disease progression by promoting angiogenesis in gastric cancer. Clin Cancer Res. 2017;23(6):1575–1585. doi:10.1158/1078-0432.CCR-16-0617
   PubMed Web of Science ®Google Scholar
• Wang YY, Zhou N, Liu HS, et al. Circulating activated lymphocyte subsets as potential blood biomarkers of cancer progression. Cancer Med. 2020;9(14):5086–5094. doi:10.1002/cam4.3150
   PubMed Web of Science ®Google Scholar
• Ravindranathan D, Master VA, Bilen MA. Inflammatory markers in cancer immunotherapy. Biology. 2021;10(4):325. doi:10.3390/biology10040325
   PubMed Web of Science ®Google Scholar
• Usiskin I, Li F, Irwin ML, et al. Association between pre-diagnosis BMI, physical activity, pathologic complete response, and chemotherapy completion in women treated with neoadjuvant chemotherapy for breast cancer. Breast Cancer. 2019;26(6):719–728. doi:10.1007/s12282-019-00974-3
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang S, Yee D, et al. Impact of body mass index on pathological complete response following neoadjuvant chemotherapy in operable breast cancer: a meta-analysis. Breast Cancer. 2021;28(3):618–629. doi:10.1007/s12282-020-01194-w
   PubMed Web of Science ®Google Scholar
• Floris G, Richard F, Hamy AS, et al. Body mass index and tumor-infiltrating lymphocytes in triple-negative breast cancer. J Natl Cancer Inst. 2021;113(2):146–153. doi:10.1093/jnci/djaa090
   PubMedGoogle Scholar
• Zeng X, Liu G, Pan Y, et al. Development and validation of immune inflammation-based index for predicting the clinical outcome in patients with nasopharyngeal carcinoma. J Cell Mol Med. 2020;24(15):8326–8349. doi:10.1111/jcmm.15097
   PubMed Web of Science ®Google Scholar
• Wang Y, Sun K, Shen J, et al. Novel prognostic nomograms based on inflammation-related markers for patients with hepatocellular carcinoma underwent hepatectomy. Cancer Res Treat. 2019;51(4):1464–1478. doi:10.4143/crt.2018.657
   PubMed Web of Science ®Google Scholar